Torrent Pharmaceuticals Ltd. announces an acquisition

Direct Assessment

The prompt's premise regarding Curatio Healthcare is incorrect. The final listing and trading approval received on July 27, 2026, pertains to the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited ("JB Chemicals") with Torrent Pharmaceuticals Limited ^[3], not Curatio Healthcare.

Regarding Curatio Healthcare, filings do not disclose an active listing-contingent scheme of amalgamation; third-party coverage indicates that Curatio Inc., a wholly owned subsidiary in the Philippines, was dissolved effective July 10, 2026 ^[4].

For the JB Chemicals Amalgamation, the receipt of final listing and trading approval from BSE and NSE on July 27, 2026 (trading effective July 28, 2026) completes the final capital-market regulatory milestone of the merger scheme ^[3]. The regulatory disclosure reports no remaining regulatory or operational conditions precedent contingent upon this listing ^[3].

---

Scheme Timeline and Listing Approval Summary

The regulatory filings set out the specific parameters and timeline for the capital restructuring stage of the amalgamation:

• Entity Amalgamated: J. B. Chemicals & Pharmaceuticals Limited (Transferor Company) merged into Torrent Pharmaceuticals Limited (Transferee Company) ^[3].
• Record Date: July 17, 2026, to determine eligible shareholders of JB Chemicals ^[3].
• Share Allotment: 4,19,22,416 fully paid-up equity shares of face value Rs 5 each allotted on July 20, 2026 ^[3].
• Exchange Approvals: Final listing and trading approvals granted by BSE Limited and the National Stock Exchange of India Limited on July 27, 2026 ^[3].
• Commencement of Trading: Shares admitted to dealings effective July 28, 2026 ^[3].

---

Regulatory and Operational Status Post-Listing

• Formal Scheme Conclusion: The admission of the 41.92 million equity shares to trading marks the formal fulfillment of the capital issuance and exchange-listing requirements under the approved Scheme of Amalgamation ^[3], ^[3].
• Remaining Contingent Conditions: The regulatory filing confirms the receipt of final listing and trading approvals without citing any further unfulfilled regulatory or operational conditions precedent that were tied to or contingent upon this listing ^[3], ^[3].
• Operational Integration Scope: While formal corporate and regulatory approvals for the merger equity issuance are complete ^[3], post-merger operational execution—such as integration of sales force coverage and realization of cost synergies—moves forward as part of ongoing business operations rather than as pending regulatory conditions precedent ^[5].

Based on the available evidence, specific valuation multiples from the Scheme of Amalgamation filings for Curatio Healthcare are not included in the text. However, secondary brokerage and market reports provide specific transaction metrics for the Curatio acquisition, while valuation multiples for other recent dermatology-focused M&A transactions in the Indian pharmaceutical sector are not disclosed in the supplied data.

Curatio Healthcare Acquisition Valuation

• Enterprise Value: Rs 1,885 Crores, derived from a total purchase consideration of Rs 2,000 Crores (which included Rs 115 Crores of cash and cash equivalents) ^[6].
• Revenue Base: Curatio reported revenue of Rs 224 Crores in FY22 (growing at a 13% CAGR over FY20–22), with expectations to cross Rs 275 Crores in FY23 ^[6].
• Valuation Multiple: The transaction was valued at 6.9x EV/FY23E Sales ^[6]. Explicit EV/EBITDA multiples from primary filing documents are not reported in the current evidence set, though secondary commentary notes that Curatio's EBITDA margins were lower than Torrent Pharma's base margins of approximately 30% ^[6].

Sector M&A Context and Disclosure Gaps

• Peer Transactions: While recent sector activity highlights dermatology and wellness deals—such as Sun Pharma increasing its stake in Taro Pharma (generic dermatology) and Cipla acquiring Ivia Beaute's personal care brands ^[7]—exact EV/Sales or EV/EBITDA transaction multiples for these comparable deals are not provided in the source material.
• Data Limits: A broad empirical comparison of acquisition cost multiples across recent dermatology deals cannot be performed from the supplied filings due to the absence of disclosed transaction multiples for peer assets.

_Scope note: this comparison also included Divi's Laboratories Ltd. (DIVISLAB); Lupin Ltd. (LUPIN); Dr. Reddy's Laboratories Ltd. (DRREDDY); Zydus Lifesciences Ltd. (ZYDUSLIFE), which the answer above does not cover. Ask about any of them for a full side-by-side._